SOURCE: Paragon Financial Limited

Paragon Financial Limited

October 19, 2012 08:20 ET

FDA Currently Considering Faster Approval Process for Drugs Deemed to Offer Societal Benefit

The Paragon Report Provides Stock Research on CEL-SCI and Peregrine Pharmaceuticals

NEW YORK, NY--(Marketwire - Oct 19, 2012) - The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on CEL-SCI Corporation (NYSE MKT: CVM) and Peregrine Pharmaceuticals (NASDAQ: PPHM).

Access to the full company reports can be found at:

www.ParagonReport.com/CVM
www.ParagonReport.com/PPHM

Under the new pathway the FDA would allow developers of such drugs to conduct smaller, faster clinical trials, and provide a "special medical use" label which would allow doctors to administer drugs to patients with critical need. Hamburg has said that the FDA needs to take into account the needs of people with deadly or debilitating diseases that may be willing to take on the risks of unproven drugs.

"A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good," said Pew Health Group's Allan Coukell, deputy director of medical programs. "It would be good for developers, for companies and it would be good for public health."

Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

CEL-SCI's mission is to improve the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational product is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

http://www.paragonreport.com/disclaimer